Avalon Consolidates Its CAR-T Enterprise By Forming Subsidiary Avactis Biosciences

Source: ar130405, no changes made, CC0 Creative Commons.
Advertisement img

Avalon GloboCare Corp. is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely “Avalon Cell” and “Avalon Rehab.” In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients’ growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories.

Avalon has formed a new wholly owned U.S. subsidiary, Avactis Biosciences, Inc., which will be focused on accelerating commercial activities related to its proprietary Chimeric Antigen Receptor (CAR)-T technologies. CAR-T is a technology that was implemented by Novartis and Gilead in two recently U.S. Food and Drug Administration (FDA) approved blood cancer cell therapies. It is a type of immunotherapy that involves genetically modifying T cells to allow them to recognize and destroy cancer cells. The new subsidiary is designed to integrate and optimize Avalon’s global scientific and clinical resources.

Avalon GloboCare’s main affiliated clinical facility, the Hebei Yanda LuDaopei Hospital, China, has completed over 300 cases of CAR-T therapy targeting CD19, CD22 and CD123, making it the single largest medical institution in CAR-T therapy in the world.  Avactis Biosciences will take on specific roles in CAR-T bio-manufacturing, standardization, and bio-banking for the LuDaopei Hospital network and other affiliated hospitals, as well as provision of collaborative research and training programs for clinicians and scientists who are involved in CAR-T therapy and technology development.

Featured Partners

“We are excited to concentrate our CAR-T activities within Avactis Biosciences and launch what we believe will become a premium CAR-T bio-enterprise.  Our proprietary, breakthrough technologies have the potential to revolutionize the manufacturing and therapeutic options for cancer patients, particularly in hematologic malignancies (such as B-ALL and non-Hodgkin Lymphoma). Our plan is to establish a unique, full-suite, integrated system for CAR-T bio-manufacturing, standardization, international multi-centered clinical studies, and intelligent biobanking, positioning Avactis Biosciences to become a key player in the CAR-T therapy sector.” David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp.



  1. https://globenewswire.com/news-release/2018/07/18/1538819/0/en/Avalon-GloboCare-Announces-Plans-to-Accelerate-Commercialization-of-Proprietary-CAR-T-Technologies-through-Launch-of-Wholly-Owned-Subsidiary-Avactis-Biosciences.html